SCHEMBL3174283

SCHEMBL3174283

[c]1cccc(OCCC2CCOCC2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.38
PDE2A O00408 1/20 0.37
TEAD1 P28347 1/20 0.36
TEAD3 Q99594 1/20 0.36
MAPK14 Q16539 2/20 0.36
MMP12 P39900 2/20 0.34
GCK P35557 1/20 0.34
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
MMP7 P09237 1/20 0.34
MMP10 P09238 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
MMP13 P45452 1/20 0.34
MMP14 P50281 1/20 0.34
MMP16 P51512 1/20 0.34
KDM1A O60341 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL919801 0.89 NFE2L2 (0.42) NFE2L2TEAD1TEAD3TAAR1
SCHEMBL3161625 0.85 CYP2D6 (0.41) MAOAMAOB
SCHEMBL27813747 0.83 NFE2L2 (0.38) NFE2L2TEAD1TEAD3TAAR1
SCHEMBL919604 0.81 HRH3 (0.38) NFE2L2TEAD1TEAD3
SCHEMBL3167048 0.81 NFE2L2 (0.45) NFE2L2PDE2ATEAD1TEAD3MAPK14
SCHEMBL921719 0.80 KCNA3 (0.38) NFE2L2TEAD1TEAD3
SCHEMBL12482465 0.79 MCHR1 (0.45) PDE2A
SCHEMBL920509 0.79 KCNA3 (0.37) NFE2L2
SCHEMBL3169944 0.79 MAOA (0.35) MAOAMAOBTAAR1
SCHEMBL919876 0.79 KCNA3 (0.37) NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1630165-B1 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF NIPPON KAYAKU KK (JP) 2010-03-31 EP disclosed
US-7598244-B2 [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 US disclosed
EP-1630165-A1 [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2006-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof HLA-C, TPMT, TAP1 NFE2L2 3155/4885PDE2A 1655/4885TEAD1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.